{'fraction_non_alphanumeric': 0.048, 'fraction_numerical': 0.02666666666666667, 'mean_word_length': 5.827272727272727, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EndothelinB (ETB) receptor‐activated potentiation of cholinergic nerve‐mediated contraction in human bronchus

In human isolated bronchial preparations, the endothelinB (ETB) receptor‐selective agonist, sarafotoxin S6c (Stx6c; 1 nM) increased nerve‐mediated contraction in response to electrical field stimulation (EFS) at 0.5‐1 Hz from 19±4% to 42±7% (n = 9). This effect was blocked in the presence of the ETB receptor‐selective antagonist, BQ‐788 (10 μm). These data are consistent with findings in some animal species that ET‐1 and related peptides have marked neuromodulatory influences on the cholinergic system. Furthermore, they provide additional support for the concept that ET‐1 may have a mediator role in bronchial obstruction in asthma.